Comparison of Pola-R-CHP and R-CHOP for newly diagnosed DLBCL: A single-center retrospective study
- 1Department of Hematology, Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan, Department of Pathology, Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan, Department of Pathology, Tokai university school of medicine, Isehara, Kanagawa, Japan
Abstract
Background: Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone (Pola-R-CHP) has become a first-line treatment option for diffuse large B-cell lymphoma (DLBCL), but real-world data remain limited. We retrospectively compared Pola-R-CHP and R-CHOP in patients with newly diagnosed DLBCL. Methods: We analyzed 127 patients who received first-line Pola-R-CHP (n = 57) or R-CHOP (n = 70) at a single center between January 2021 and August 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and adverse events. A 120-day landmark analysis, subgroup analyses, and exploratory analysis for sepsis were also performed. Results: Median age was 75 years in the Pola-R-CHP group and 79.5 years in the R-CHOP group; patients aged >80 years were more frequent in the R-CHOP group (21.1% vs 47.1%, P = 0.003). 1-year PFS was 83.9% with Pola-R-CHP and 76.9% with R-CHOP (P = 0.56). 1-year OS was 89.8% and 91.1%, respectively (P = 0.61). In the 120-day landmark analysis, no significant difference in PFS was observed (HR 0.68, 95% CI 0.29–1.56, P = 0.36). Infection-related treatment discontinuation was more frequent with Pola-R-CHP (12.3% vs 0%, P = 0.003). Sepsis was also more frequent in the Pola-R-CHP group (14.0% vs 4.3%, P = 0.098). Conclusions: In this single-center retrospective cohort, Pola-R-CHP was not associated with a significant improvement in PFS compared with R-CHOP. Infection-related treatment discontinuation was more frequent in the Pola-R-CHP group. Sepsis was also numerically more frequent, highlighting the importance of careful infection monitoring in clinical practice.
Related
- Safety and feasibility of peripherally inserted central catheter (PICC) placement in patients with newly diagnosed acute leukemia: A single-center retrospective study
- Development and Internal Validation of a Pilot Model for Newly Diagnosed in-Hospital Bacterial and Fungal Infections in Decompensated Hepatitis B Cirrhosis: A Single-Center Retrospective Cohort Study
- Circulating tumor plasma cells correlate with tumor burden and routine laboratory markers in newly diagnosed multiple myeloma: A retrospective single-center study.
- Anthracycline-Free FLA-VEN with or Without Midostaurin in Newly Diagnosed Intermediate- and Adverse-Risk AML: A Single-Center Retrospective Study.
- AI-Generated Treatment Recommendations in Newly Diagnosed Lung Cancer: A Single-Center Feasibility Study in a Resource-Limited Setting.
BibTeX
@article{akita2026comparison,
title = {{Comparison of Pola-R-CHP and R-CHOP for newly diagnosed DLBCL: A single-center retrospective study}},
author = {Kaori Akita and Atsushi Takahata and Wataru Tokuyama and Naoya Nakamura and Shigeo Toyota},
journal = {Journal of Clinical and Experimental Hematopathology : JCEH},
year = {2026},
month = jul,
doi = {10.3960/jslrt.26017},
url = {https://doi.org/10.3960/jslrt.26017},
note = {CC BY-NC-SA 4.0},
}
RIS
TY - JOUR
TI - Comparison of Pola-R-CHP and R-CHOP for newly diagnosed DLBCL: A single-center retrospective study
AU - Kaori Akita
AU - Atsushi Takahata
AU - Wataru Tokuyama
AU - Naoya Nakamura
AU - Shigeo Toyota
PY - 2026
DA - 2026/07/30
JO - Journal of Clinical and Experimental Hematopathology : JCEH
DO - 10.3960/jslrt.26017
UR - https://doi.org/10.3960/jslrt.26017
AB - Background: Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone (Pola-R-CHP) has become a first-line treatment option for diffuse large B-cell lymphoma (DLBCL), but real-world data remain limited. We retrospectively compared Pola-R-CHP and R-CHOP in patients with newly diagnosed DLBCL. Methods: We analyzed 127 patients who received first-line Pola-R-CHP (n = 57) or R-CHOP (n = 70) at a single center between January 2021 and August 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and adverse events. A 120-day landmark analysis, subgroup analyses, and exploratory analysis for sepsis were also performed. Results: Median age was 75 years in the Pola-R-CHP group and 79.5 years in the R-CHOP group; patients aged >80 years were more frequent in the R-CHOP group (21.1% vs 47.1%, P = 0.003). 1-year PFS was 83.9% with Pola-R-CHP and 76.9% with R-CHOP (P = 0.56). 1-year OS was 89.8% and 91.1%, respectively (P = 0.61). In the 120-day landmark analysis, no significant difference in PFS was observed (HR 0.68, 95% CI 0.29–1.56, P = 0.36). Infection-related treatment discontinuation was more frequent with Pola-R-CHP (12.3% vs 0%, P = 0.003). Sepsis was also more frequent in the Pola-R-CHP group (14.0% vs 4.3%, P = 0.098). Conclusions: In this single-center retrospective cohort, Pola-R-CHP was not associated with a significant improvement in PFS compared with R-CHOP. Infection-related treatment discontinuation was more frequent in the Pola-R-CHP group. Sepsis was also numerically more frequent, highlighting the importance of careful infection monitoring in clinical practice.
SN - 1346-4280
SN - 1880-9952
ER -